Beta Drugs Limited (BDL), a leading Indian manufacturer of oncology medicines, has received approval from the Drug Controller General of India (DCGI) to launch Methotrexate Solution for Oral Use. With this milestone, BDL becomes the first company in India to introduce a patient-friendly, bioequivalent oral formulation of Methotrexate.
A Safer and Easier Alternative for Patients
Methotrexate, a globally recognized therapy for oncology and autoimmune disorders, has traditionally been available in tablet and injectable forms. These formats often pose challenges in dosing and administration, particularly for pediatric, geriatric, and chronic-care patients. The newly approved oral solution offers an accurately dosed, easy-to-administer, and bioequivalent alternative, enhancing treatment compliance, safety, and convenience under medical supervision.
Wide Range of Indications
The Methotrexate Oral Solution is indicated for multiple conditions, including acute lymphoblastic leukemia (ALL), lymphomas, and solid tumors, as well as autoimmune diseases such as Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and various forms of Psoriasis—including Chronic Plaque Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis, and Pustular Psoriasis.
Expanding Beyond Oncology
As per the Beta Drug press release, this first-to-market approval marks a strategic step for Beta Drugs as it expands its reach beyond oncology into autoimmune therapy segments. The company, already known for its strong presence in oncology and dermatology, aims to broaden its therapeutic portfolio and strengthen its leadership in these fast-growing areas.
Growing Market Opportunities
The global methotrexate market continues to grow. This growth is driven by the limited availability of alternatives offering similar therapeutic benefits for ALL, autoimmune, and inflammatory diseases. The introduction of an oral formulation opens new opportunities across pediatric, hospital, and chronic-care settings. It also creates potential for robust domestic and export growth.
Commitment to Patient-Centric Innovation
This approval reinforces Beta Drugs’ commitment to innovative, affordable, and patient-centric therapies that enhance treatment access and quality of life. By pioneering differentiated formulations like Methotrexate Oral Solution, the company continues to advance its mission. It aims to deliver high-quality, accessible medicines for cancer and other critical conditions.